HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 6 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $424,593 | -64.7% | 11,115 | -66.7% | 0.00% | -60.0% |
| Q2 2023 | $1,204,017 | +279.8% | 33,380 | +302.2% | 0.01% | +400.0% |
| Q1 2023 | $316,977 | -78.5% | 8,300 | -68.0% | 0.00% | -87.5% |
| Q4 2022 | $1,474,620 | +532.9% | 25,916 | +339.6% | 0.01% | +300.0% |
| Q3 2022 | $233,000 | -61.2% | 5,895 | -60.5% | 0.00% | -66.7% |
| Q4 2021 | $600,000 | -24.5% | 14,912 | -23.7% | 0.01% | -40.0% |
| Q3 2021 | $795,000 | +26.2% | 19,552 | +40.8% | 0.01% | +11.1% |
| Q2 2021 | $630,000 | -4.0% | 13,884 | -11.8% | 0.01% | -18.2% |
| Q1 2021 | $656,000 | +32.8% | 15,743 | +36.0% | 0.01% | +22.2% |
| Q4 2020 | $494,000 | +308.3% | 11,578 | +151.4% | 0.01% | +200.0% |
| Q3 2020 | $121,000 | -1.6% | 4,606 | -31.9% | 0.00% | -40.0% |
| Q3 2018 | $123,000 | +186.0% | 6,765 | +218.4% | 0.01% | +66.7% |
| Q4 2017 | $43,000 | – | 2,125 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SNYDER CAPITAL MANAGEMENT L P | 4,324,232 | $165,185,662 | 3.73% |
| Steamboat Capital Partners, LLC | 196,898 | $7,521,504 | 2.79% |
| 2Xideas AG | 600,799 | $22,950,522 | 2.54% |
| BERNZOTT CAPITAL ADVISORS | 171,808 | $6,563,066 | 2.26% |
| Redwood Investments, LLC | 328,459 | $12,547,134 | 1.70% |
| Mesirow Institutional Investment Management, Inc. | 380,415 | $14,531,853 | 1.47% |
| Granite Investment Partners, LLC | 856,253 | $32,708,865 | 1.37% |
| Penn Capital Management Company, LLC | 324,707 | $12,453,211 | 1.28% |
| EFG Asset Management (North America) Corp. | 137,739 | $5,262,319 | 1.25% |
| First Light Asset Management, LLC | 313,536 | $11,977,075 | 1.14% |